68Ga- or 18F-FAPI PET/CT—what it can and cannot

[1]  U. Haberkorn,et al.  FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease. , 2023, Radiology.

[2]  H. Kauczor,et al.  Repetitive Early 68Ga-FAPI PET Acquisition Comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions , 2022, The Journal of Nuclear Medicine.

[3]  H. Kauczor,et al.  18F-labeled tracers targeting fibroblast activation protein , 2021, EJNMMI Radiopharmacy and Chemistry.

[4]  M. Röhrich,et al.  FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients , 2020, The Journal of Nuclear Medicine.

[5]  H. Kauczor,et al.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.

[6]  Thomas Lindner,et al.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.

[7]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers , 2018, The Journal of Nuclear Medicine.

[8]  F. Giesel,et al.  68Ga or 18F for Prostate Cancer Imaging? , 2017, The Journal of Nuclear Medicine.

[9]  U. Haberkorn,et al.  Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging , 2017, The Journal of Nuclear Medicine.

[10]  F. Wuest,et al.  18F-Labeled Peptides: The Future Is Bright , 2014, Molecules.

[11]  W. Mcbride,et al.  A Novel Method of 18F Radiolabeling for PET , 2009, Journal of Nuclear Medicine.

[12]  H. Kauczor,et al.  Repetitive early FAPI-PET acquisition comparing FAPI-02, FAPI-46 and FAPI-74: methodological and diagnostic implications for malignant, inflammatory and degenerative lesions , 2022 .